GSK3 and P53 - is There a Link in Alzheimer's Disease?

Overview

Journal Mol Neurodegener

Publisher Biomed Central

Specialties Molecular Biology
Neurology

Date 2010 Feb 26

PMID 20181016

Citations 36

Authors

Carole J Proctor

Douglas A Gray

Affiliations

Soon will be listed here.

Abstract

Background: Recent evidence suggests that glycogen synthase kinase-3beta (GSK3beta) is implicated in both sporadic and familial forms of Alzheimer's disease. The transcription factor, p53 also plays a role and has been linked to an increase in tau hyperphosphorylation although the effect is indirect. There is also evidence that GSK3beta and p53 interact and that the activity of both proteins is increased as a result of this interaction. Under normal cellular conditions, p53 is kept at low levels by Mdm2 but when cells are stressed, p53 is stabilised and may then interact with GSK3beta. We propose that this interaction has an important contribution to cellular outcomes and to test this hypothesis we developed a stochastic simulation model.

Results: The model predicts that high levels of DNA damage leads to increased activity of p53 and GSK3beta and low levels of aggregation but if DNA damage is repaired, the aggregates are eventually cleared. The model also shows that over long periods of time, aggregates may start to form due to stochastic events leading to increased levels of ROS and damaged DNA. This is followed by increased activity of p53 and GSK3beta and a vicious cycle ensues.

Conclusions: Since p53 and GSK3beta are both involved in the apoptotic pathway, and GSK3beta overactivity leads to increased levels of plaques and tangles, our model might explain the link between protein aggregation and neuronal loss in neurodegeneration.

Citing Articles

Complex p53 dynamics regulated by miR-125b in cellular responses to reactive oxidative stress and DNA damage.

Malik M, Dashti M, Jangid A, Channanath A, John S, Brojen Singh R Brief Bioinform. 2025; 26(1.

PMID: 39820247 PMC: 11736902. DOI: 10.1093/bib/bbae706.

5,7,4'-Trimethoxyflavone triggers cancer cell PD-L1 ubiquitin-proteasome degradation and facilitates antitumor immunity by targeting HRD1.

Xia J, Xu M, Hu H, Zhang Q, Yu D, Cai M MedComm (2020). 2024; 5(7):e611.

PMID: 38938284 PMC: 11208742. DOI: 10.1002/mco2.611.

The role of microRNAs in understanding sex-based differences in Alzheimer's disease.

Llera-Oyola J, Carceller H, Andreu Z, Hidalgo M, Soler-Saez I, Gordillo F Biol Sex Differ. 2024; 15(1):13.

PMID: 38297404 PMC: 10832236. DOI: 10.1186/s13293-024-00588-1.

Altered synaptic plasticity at hippocampal CA1-CA3 synapses in Alzheimer's disease: integration of amyloid precursor protein intracellular domain and amyloid beta effects into computational models.

Dainauskas J, Vitale P, Moreno S, Marie H, Migliore M, Saudargiene A Front Comput Neurosci. 2023; 17:1305169.

PMID: 38130706 PMC: 10733499. DOI: 10.3389/fncom.2023.1305169.

Morphological connectivity differences in Alzheimer's disease correlate with gene transcription and cell-type.

Yu H, Ding Y, Wei Y, Dyrba M, Wang D, Kang X Hum Brain Mapp. 2023; 44(18):6364-6374.

PMID: 37846762 PMC: 10681645. DOI: 10.1002/hbm.26512.

References

Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow E . Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999; 38(12):3549-58. DOI: 10.1021/bi981874p. View

Lahav G, Rosenfeld N, Sigal A, Geva-Zatorsky N, Levine A, Elowitz M . Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet. 2004; 36(2):147-50. DOI: 10.1038/ng1293. View

Dickey C, Koren J, Zhang Y, Xu Y, Jinwal U, Birnbaum M . Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A. 2008; 105(9):3622-7. PMC: 2265134. DOI: 10.1073/pnas.0709180105. View

Le Novere N, Bornstein B, Broicher A, Courtot M, Donizelli M, Dharuri H . BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems. Nucleic Acids Res. 2005; 34(Database issue):D689-91. PMC: 1347454. DOI: 10.1093/nar/gkj092. View

Hooper C, Killick R, Lovestone S . The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2007; 104(6):1433-9. PMC: 3073119. DOI: 10.1111/j.1471-4159.2007.05194.x. View

Pap M, Cooper G . Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem. 1998; 273(32):19929-32. DOI: 10.1074/jbc.273.32.19929. View

Roe C, Behrens M, Xiong C, Miller J, Morris J . Alzheimer disease and cancer. Neurology. 2005; 64(5):895-8. DOI: 10.1212/01.WNL.0000152889.94785.51. View

Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A . CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet. 2004; 13(7):703-14. DOI: 10.1093/hmg/ddh083. View

Watcharasit P, Bijur G, Song L, Zhu J, Chen X, Jope R . Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem. 2003; 278(49):48872-9. PMC: 1361697. DOI: 10.1074/jbc.M305870200. View

10.

Arai T, Guo J, McGeer P . Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem. 2004; 280(7):5145-53. DOI: 10.1074/jbc.M409234200. View

11.

Hardy J, Allsop D . Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991; 12(10):383-8. DOI: 10.1016/0165-6147(91)90609-v. View

12.

Hoeflich K, Luo J, Rubie E, Tsao M, Jin O, Woodgett J . Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000; 406(6791):86-90. DOI: 10.1038/35017574. View

13.

David D, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini M . Proteasomal degradation of tau protein. J Neurochem. 2002; 83(1):176-85. DOI: 10.1046/j.1471-4159.2002.01137.x. View

14.

Hooper C, Meimaridou E, Tavassoli M, Melino G, Lovestone S, Killick R . p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett. 2007; 418(1):34-7. PMC: 1885960. DOI: 10.1016/j.neulet.2007.03.026. View

15.

Kirkwood T, Boys R, Gillespie C, Proctor C, Shanley D, Wilkinson D . Towards an e-biology of ageing: integrating theory and data. Nat Rev Mol Cell Biol. 2003; 4(3):243-9. DOI: 10.1038/nrm1051. View

16.

Eidenmuller J, Fath T, Hellwig A, Reed J, Sontag E, Brandt R . Structural and functional implications of tau hyperphosphorylation: information from phosphorylation-mimicking mutated tau proteins. Biochemistry. 2000; 39(43):13166-75. DOI: 10.1021/bi001290z. View

17.

Dickey C, Kamal A, Lundgren K, Klosak N, Bailey R, Dunmore J . The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest. 2007; 117(3):648-58. PMC: 1794119. DOI: 10.1172/JCI29715. View

18.

Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, Boyer N . Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci. 2006; 26(23):6377-85. PMC: 6675197. DOI: 10.1523/JNEUROSCI.0651-06.2006. View

19.

Bijur G, Jope R . Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem. 2001; 276(40):37436-42. PMC: 1973163. DOI: 10.1074/jbc.M105725200. View

20.

Donehower L . Does p53 affect organismal aging?. J Cell Physiol. 2002; 192(1):23-33. DOI: 10.1002/jcp.10104. View